Lymphoma, T-Cell, Cutaneous
Information
- Disease name
- Lymphoma, T-Cell, Cutaneous
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02953301 | Active, not recruiting | Phase 2 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) | November 2016 | June 2024 |
| NCT04998331 | Active, not recruiting | A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin | October 29, 2021 | June 30, 2024 | |
| NCT03902184 | Active, not recruiting | Phase 2 | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma | May 22, 2019 | October 31, 2024 |
| NCT00051597 | Completed | Phase 1/Phase 2 | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | August 2003 | |
| NCT00211198 | Completed | Phase 4 | Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) | May 2001 | January 2006 |
| NCT00896493 | Completed | Phase 2 | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma | May 2009 | December 2022 |
| NCT01433731 | Completed | Phase 1 | Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) | November 2011 | September 2013 |
| NCT01486277 | Completed | Phase 2 | A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma | November 2011 | July 2016 |
| NCT02181218 | Completed | Phase 1 | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | February 4, 2015 | June 26, 2020 |
| NCT00001249 | Completed | Phase 1 | Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac | December 1989 | October 2000 |
| NCT02567656 | Completed | Phase 1 | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma | September 2015 | December 10, 2018 |
| NCT03302728 | Completed | Phase 1 | Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma | August 30, 2018 | August 2, 2021 |
| NCT00050999 | Completed | Phase 4 | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients | June 1995 | December 2006 |
| NCT00051012 | Completed | Phase 4 | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients | September 1995 | December 2006 |
| NCT00043420 | Completed | Phase 1/Phase 2 | CPG 7909 in Patients With Cutaneous T-Cell Lymphoma | January 2003 | March 2007 |
| NCT05137847 | Completed | A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) | May 24, 2021 | March 17, 2023 | |
| NCT03192202 | Completed | Phase 1/Phase 2 | AFM13 in Relapsed/Refractory Cutaneous Lymphomas | July 17, 2017 | April 1, 2020 |
| NCT02836886 | Completed | VircapSeq Virus Detection in Sézary Syndrome | June 2016 | October 2016 | |
| NCT05827107 | Enrolling by invitation | Skin Barrier and Microbiome of CTCL Patients | April 3, 2023 | January 2025 | |
| NCT01196208 | No longer available | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 | |||
| NCT00419367 | No longer available | Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) | |||
| NCT06120504 | Recruiting | Phase 1 | A Safety Study of SGN-35T in Adults With Advanced Cancers | February 29, 2024 | April 30, 2030 |
| NCT02840747 | Recruiting | Tissue Repository: CTCL Collection Protocol | July 2016 | January 2025 | |
| NCT03646422 | Recruiting | AEDV Registry of Primary Cutaneous Lymphoma | September 1, 2016 | January 1, 2025 | |
| NCT05138458 | Suspended | Phase 1/Phase 2 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | December 15, 2021 | October 2025 |
| NCT03789864 | Terminated | N/A | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides | October 7, 2019 | May 1, 2024 |
| NCT03601819 | Terminated | Phase 1 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | May 15, 2019 | July 17, 2020 |
| NCT03357224 | Terminated | Phase 2 | PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) | September 24, 2018 | August 18, 2022 |
| NCT02811783 | Terminated | Phase 3 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL | January 2017 | September 2022 |
| NCT02323659 | Terminated | Phase 4 | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas | June 1, 2014 | March 31, 2018 |
| NCT03116659 | Unknown status | Early Phase 1 | CTCL Directed Therapy | February 1, 2018 | December 30, 2020 |
| NCT03563040 | Withdrawn | Phase 2 | Study of Photopheresis in the Treatment of Erythrodermic MF and SS | December 1, 2020 | June 1, 2026 |
| NCT03742804 | Withdrawn | Phase 2 | Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma | June 2019 | December 2022 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D016410